| Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis | 2023 | Frontiers in oncology |
| Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis | 2023 | Critical reviews in oncology/hematology |
| Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis | 2023 | Journal of cancer research |
| Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations | 2023 | European journal of clinical pharmacology |
| Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis | 2023 | Journal of cancer |
| Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis | 2023 | Clinics and research in hepatology and gastroenterology |
| Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis | 2023 | Medicine |
| Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis | 2023 | Cost effectiveness and resource allocation |
| Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis | 2023 | Frontiers in pharmacology |
| Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis | 2023 | Clinical and experimental hepatology |
| How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. | 2022 | Frontiers in Oncology |
| Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | The Journal of Urology |
| Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | European Urology Open Science |
| Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. | 2022 | Therapeutic Advances in Medical Oncology |
| Clinical and pharmacoeconomic combined report. | 2022 | CADTH |
| Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. | 2022 | Cancer Medicine |
| Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta-analysis. | 2022 | The Journal of Clinical Hypertension |
| Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. | 2022 | Frontiers in Oncology |
| Lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2022 | Cancers |
| IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time | 2022 | Seminars in oncology |
| Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis | 2022 | Frontiers in pharmacology |
| New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis | 2022 | Cancer treatment reviews |
| The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis | 2022 | International immunopharmacology |
| Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis | 2022 | Medicine |
| Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study | 2022 | Anticancer research |
| Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2021 | American Journal of Translational Research |
| Efficacy of first line systemic chemotherapy and multikinase inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2021 | Frontiers in Oncology |
| Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. | 2021 | Journal of Hepatocellular Cancer |
| Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. | 2021 | Liver Cancer |
| Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. | 2021 | Critical Reviews in Oncology/ Hematology |
| Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). | 2021 | Gastroenterology |
| Clinical efficacy of lenvatinib for the treatment of radioiodinerefractory thyroid carcinoma: a systematic review and meta-analysis of clinical trials. | 2021 | Clinical Endocrinology |
| Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. | 2021 | Journal of the National Cancer Institute |
| Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. | 2021 | World Journal of Gastroenterology |
| A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. | 2021 | Expert Review of Anticancer Therapy |
| A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis | 2021 | Current opinion in urology |
| First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis | 2021 | European urology oncology |
| First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials | 2021 | Frontiers in oncology |
| Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario | 2021 | Canadian liver journal |
| Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. | 2020 | NIHR |
| Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2020 | JAMA Oncology |
| Australian public assessment report: for lenvatinib. | 2020 | Australian Government: Department of Health |
| Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials | 2020 | Hormone and metabolic research |
| A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. | 2019 | BMC Cancer |
| Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. | 2019 | BMJ Open |
| Final clinical guidance report: Lenvima for renal cell carcinoma. | 2019 | CADTH |
| Final clinical guidance report: Lenvima for hepatocellular carcinoma. | 2019 | CADTH |
| Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis | 2019 | Cancer management and research |
| Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials | 2019 | Journal of clinical gastroenterology |
| Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma | 2019 | PloS one |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. | 2018 | NICE |
